Cisplatin for Lung Cancer: 105 Real Stories

105 stories match lung cancer and cisplatin. 103 of them mention chemotherapy.

A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIB lung adenocarcinoma with separate papillary renal cell carcinoma: doing well more than 6 years after revised diagnosis

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Lung tumor: TTF-1-positive; PET-avid. Kidney lesion: PET-negative; later papillary renal cell carcinoma. No lung molecular biomarkers reported.

As of February 2014, she was doing well more than 6 years after the initial diagnosis, after the diagnosis was revised from presumed Stage IV lung cancer to Stage IIIB lung adenocarcinoma plus a separate papillary renal cell carcinoma.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage IIIA squamous lung cancer with later kidney and paraaortic lymph node metastases

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Squamous lung cancer markers supported the diagnosis; TTF-1, CK7 and CK20 were not seen; Ki-67 >10%.

Metastatic Site: left renal parenchyma, paraaortic lymph nodes

After surgery, 4 cycles of cisplatin plus vinblastine, and mediastinal radiotherapy, she had a 10-month disease-free interval before biopsy-confirmed metastatic squamous lung carcinoma appeared in the left kidney with paraaortic lymph node enlargement.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV lung adenocarcinoma with brain metastasis: partial remission after pemetrexed/cisplatin and AOSD-like paraneoplastic syndrome

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: No tumor molecular biomarkers reported. AOSD-like syndrome had high ferritin, inflammation markers, and RF/ANA negative.

Metastatic Site: brain

As of November 2011, pemetrexed/cisplatin produced partial remission of Stage IV lung adenocarcinoma and controlled the AOSD-like paraneoplastic syndrome without recurrent fever, rash, or arthralgia.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV lung adenocarcinoma: partial responses to cisplatin-docetaxel and erlotinib, complicated by fistula

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Tumor genomic biomarkers not reported. EGFR testing result not reported; erlotinib was used as second-line therapy.

Metastatic Site: contralateral lung, pleura

Metastatic lung adenocarcinoma had partial response to chemotherapy and persistent partial response on erlotinib; after erlotinib was stopped for enterocutaneous fistula, she was alive and well without evidence of lung-cancer progression.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Large cell lung carcinoma with solitary jejunal metastasis: no evidence of disease 4 years after treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Primary lung tumor and jejunal metastasis shared a KRAS codon 61 mutation; staining supported lung origin.

Metastatic Site: jejunum

As of January 2010, she was doing well with no evidence of disease 4 years after diagnosis and treatment of a solitary jejunal metastasis from large cell lung carcinoma.

PubMed Central
OutcomeCancer-Free / NED